Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemabFREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. NASDAQ:ALMR, a leader in precision proteomics dedicated to enabling the earliest detecti…